These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30854558)

  • 1. Use of a Blast Dominance-Hematogone Index for the Flow Cytometric Evaluation of Myelodysplastic Syndrome (MDS).
    Schenkel JM; Hergott CB; Dudley G; Drew M; Charest K; Dorfman DM
    Am J Clin Pathol; 2019 May; 151(6):584-592. PubMed ID: 30854558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparameter flow cytometric analysis reveals low percentage of bone marrow hematogones in myelodysplastic syndromes.
    Maftoun-Banankhah S; Maleki A; Karandikar NJ; Arbini AA; Fuda FS; Wang HY; Chen W
    Am J Clin Pathol; 2008 Feb; 129(2):300-8. PubMed ID: 18208811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
    Shameli A; Dharmani-Khan P; Luider J; Auer I; Shabani-Rad MT
    Cytometry B Clin Cytom; 2021 Sep; 100(5):574-589. PubMed ID: 33369070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
    Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
    Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
    Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualitative flow cytometric analysis of Malaysian myelodysplastic syndromes (MDS) patients.
    Mohadese Hashem B; Rajesh R; Sabariah MN; Zainina BS
    Med J Malaysia; 2012 Feb; 67(1):77-80. PubMed ID: 22582553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Four-color flow cytometric immunophenotypic features of blasts in myelodysplastic syndromes].
    Wu YJ; Li JY; Qiu HR; Xiao B; Zhang JF; Song JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):50-3. PubMed ID: 16584591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.
    Majcherek M; Kiernicka-Parulska J; Mierzwa A; Barańska M; Matuszak M; Lewandowski K; Komarnicki M; Czyż A
    Scand J Immunol; 2021 Aug; 94(2):e13028. PubMed ID: 33577137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Grade Myelodysplastic Syndromes with Preserved CD34+ B-Cell Precursors (CD34+ Hematogones).
    Chen Z; Ok CY; Wang W; Goswami M; Tang G; Routbort M; Jorgensen JL; Medeiros LJ; Wang SA
    Cytometry B Clin Cytom; 2020 Jan; 98(1):36-42. PubMed ID: 31211490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes.
    Xie W; Wang X; Du W; Liu W; Qin X; Huang S
    Cytometry A; 2010 Sep; 77(9):840-8. PubMed ID: 20662087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of blast heterogeneity in myelodysplastic syndrome and other chronic myeloid neoplasms.
    Jevremovic D; Timm MM; Reichard KK; Morice WG; Hanson CA; Viswanatha DS; Howard MT; Nguyen PL
    Am J Clin Pathol; 2014 Sep; 142(3):292-8. PubMed ID: 25125617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Ia (HLA-DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromes.
    Mittelman M; Karcher DS; Kammerman LA; Lessin LS
    Am J Hematol; 1993 Jul; 43(3):165-71. PubMed ID: 8352230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination of CD15/CD10, CD64/CD33, CD16/CD13 or CD11b flow cytometric granulocyte panels is sensitive and specific for diagnosis of myelodysplastic syndrome.
    Chung JW; Park CJ; Cha CH; Cho YU; Jang S; Chi HS; Seo EJ; Lee JH; Lee JH; Lee KH; Im HJ; Seo JJ
    Ann Clin Lab Sci; 2012; 42(3):271-80. PubMed ID: 22964615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-color CD34⁺ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia.
    Tang G; Jorgensen LJ; Zhou Y; Hu Y; Kersh M; Garcia-Manero G; Medeiros LJ; Wang SA
    Leuk Res; 2012 Aug; 36(8):974-81. PubMed ID: 22626984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of blast immunophenotypes in myelodysplastic syndromes.
    Ogata K; Yoshida Y
    Leuk Lymphoma; 2005 Sep; 46(9):1269-74. PubMed ID: 16109603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.
    Falco P; Levis A; Stacchini A; Ciriello MM; Geuna M; Notari P; Omedè P; Pautasso M; Prato G; Strola G; Gioia D; Bonferroni M; Cametti G; Ferrero D; Freilone R; Gaidano G; Marinone C; Marmont F; Pollio B; Salvi F; Saglio G; Girotto M;
    Eur J Haematol; 2011 Nov; 87(5):409-18. PubMed ID: 21711395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Abnormality of immunophenotyping in patients with myelodysplastic syndrome].
    Xu J; Guo YX; Zhao H; Hui WH; Wan SG; Sun XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):894-7. PubMed ID: 19698224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
    Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
    Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.